Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

详细信息    查看全文

• 作者：Chan Y. Cheah ; Paul J. Brö ; ckelmann ; Dai Chihara ; Alison J. Moskowitz ; Andreas Engert ; Mats Jerkeman ; Tarec C. El-Galaly ; Bradley Augustson ; Julie Vose ; Nancy L. Bartlett ; Diego Villa ; Joseph M. Connors ; Tatyana Feldman ; Chelsea C. Pinnix ; Sarah A. Milgrom ; Bouthaina Dabaja ; Yasuhiro Oki and Michelle A. Fanale
• 刊名：American Journal of Hematology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：91
• 期：9
• 页码：894-899
• 全文大小：462K
• ISSN：1096-8652

文摘

Central nervous system (CNS) involvement is rare in patients with Hodgkin lymphoma (HL). Thus, the clinical features and outcomes are not well described. Cases of histologically confirmed CNS HL diagnosed between 1995 and 2015 were retrospectively identified in institutional (n = 7), national (n = 2), and cooperative group (n = 1) databases. We screened 30,781 patients with HL in our combined databases and identified 21 patients meeting eligibility criteria, an estimated frequency of 0.07%. CNS involvement was present at initial diagnosis in 10 patients (48%) and a feature of relapsed/refractory disease in 11 (52%). Among these 11 patients, the median time from initial diagnosis of HL to development of CNS involvement was 1.9 years (range 0.4–6.6) and the median number of prior lines of therapy was 2 (range 1–7). Altogether, treatments included radiation, multiagent systemic chemotherapy, combined modality therapy, and subtotal resection. The overall response rate was 65%. After a median follow-up of 3.6 years (range 0.8–13.2) from diagnosis of CNS HL, the median PFS and OS were 7.6 and 29 months, respectively. CNS involvement as a feature of relapsed/refractory disease was adversely prognostic for both PFS and OS; however, four patients remain alive and free of relapse at 7–78 months follow-up. CNS involvement in HL is exceedingly rare and has a distinct clinical presentation with predilection for parenchymal lesions with dural extension. Around one-quarter of patients, mostly with CNS involvement at initial HL diagnosis, experience prolonged disease-free survival. Am. J. Hematol. 91:894–899, 2016.